Disarm Therapeutics
Business Services · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1 Main St Ste 11, Cambridge, Massachuset...Phone Number
(617) 752-6884Revenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Disarm Therapeutics
Disarm Therapeutics is a biotechnology company founded in 2016 that develops disease-modifying therapeutics for patients with axonal degeneration, a key factor in neurological disability and disease progression. The company focuses on inhibiting the SARM1 protein to prevent axon loss in chronic and acute diseases affecting the central, ocular, and peripheral nervous systems. Their therapeutic approach aims to prevent further degeneration, stabilize disease, and enable functional recovery for conditions including multiple sclerosis, amyotrophic lateral sclerosis, glaucoma, and peripheral neuropathies. Now part of Lilly's research and scientific discovery division, Disarm Therapeutics continues its mission to create new treatment paradigms for patients with neurological diseases.Explore more
Disarm Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Disarm Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Disarm Therapeutics launches new products
Disarm Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Disarm Therapeutics
Earning: See what the market has to say on Disarm Therapeutics recently announced quarterly report
Check if Disarm Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Check out if Disarm Therapeutics is spiking on competitors!
Click to see if Disarm Therapeutics had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Disarm Therapeutics has new funding data
Recommended Actions
Find VP level buyers at Disarm Therapeutics
Find 2 more new buyers
Compare Similar Companies to Disarm Therapeutics
Compare insights from companies similar to Disarm Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Disarm Therapeutics
<$5M
11-50
Private
$30M
2016
LL
Liza LeventhalSenior Director, Pharmacology & Research Operations
$65.8B
10K+
Public
$20.9B
1891
AM
Allyson MunsellChief of Staff To the Senior Vice President, Global Communications
$56.7B
10K+
Public
-
1996
DC
Daniela CastanedaImmunology Director, Commercial Operations & Chief of Staff
$48.5B
10K+
Public
$4B
1887
IC
Imara CharlesVice President, Chief of Staff, Global Product Development & Supply
Company Profile Activity
Activity Insights
Disarm Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Disarm Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Disarm Therapeutics.
Disarm Therapeutics financials insights
Gather financial insights about Disarm Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Series A
$30M
Most Recent Scoops
Left Company
Executive Move
Left Company
Executive Move
Mergers & Acquisitions (M&A)
Management Move
Executive Move
Executive Moves
Promotion
Management Move
Executive Move
Executive Moves, New Hire, Promotion
Disarm Therapeutics News & Media
Eli Lilly Acquires Disarm Therapeutics in an Effort to Solve Axonal Degeneration
Eli Lilly is betting on a new approach to axonal degeneration, announcing a definitive agreement to acquire Disarm Therapeutics, a privately-held biotech company committed to solving this mystery.Disarm Therapeutics Appoints Veteran Biotech Executive Scott Holmes as Chief Financial Officer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Disarm Therapeutics announced the appointment of Scott Holmes, M.S./MBA, as Chief Financial Officer.Disarm Therapeutics Appoints Veteran Biotech Executive Scott Holmes as Chief Financial Officer
Disarm Therapeutics, a biotechnology company creating a new class of disease-modifying therapeutics for patients with axonal degeneration, today announced the appointment of Scott Holmes, M.S./MBA, as Chief Financial OfficerDisarm Therapeutics Announces Appointment of Dr. Alvin Shih as President and Chief Executive Officer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Disarm Therapeutics announces appointment of Alvin Shih, M.D., MBA, as President and CEO.
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Disarm Therapeutics
Sign Up For FreeTo access detailed company insights
Disarm Therapeutics is a biotechnology company founded in 2016 that develops disease-modifying therapeutics for patients with axonal degeneration, a key factor in neurological disability and disease progression. The company focuses on inhibiting the SARM1 protein to prevent axon loss in chronic and acute diseases affecting the central, ocular, and... Read More
